Metric Finance
LearnFAQ
LearnFAQ

Learn / KRSA

NASDAQ: KRSA

Korsana Biosciences (KRSA) stock, explained like you're 5

Korsana Biosciences trades on the Nasdaq under the ticker KRSA. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 1.5 billion dollars.

Ticker
KRSA
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Small cap, about 1.5 billion dollars

Is Korsana Biosciences a small, medium or large cap company?

No. Korsana Biosciences is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 1.5 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Korsana Biosciences makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves KRSA stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Korsana Biosciences (KRSA) Stock Price, News & Analysis (Stock Titan)
  • Net current asset value per share of Korsana Biosciences, Inc. NASDAQ:KRSA (TradingView)
  • Korsana Biosciences (KRSA) At $31.20 Leaves Valuation Questions On A Sharp 2026 Run (Yahoo Finance)
  • symbol__ Stock Quote Price and Forecast (CNN)
  • A 25,974 share stake in Korsana Biosciences (KRSA) is held by J. Wood Capital Advisors. (Stock Titan)

Follow KRSA in your daily brief

Each trading day at 5 PM ET we post what happened to Korsana Biosciences and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow KRSA

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Korsana Biosciences stock

What does Korsana Biosciences do?

Korsana Biosciences trades on the Nasdaq under the ticker KRSA. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 1.5 billion dollars.

What is the ticker symbol for Korsana Biosciences?

Korsana Biosciences trades under the ticker KRSA on the Nasdaq.

What is Korsana Biosciences's market cap?

Korsana Biosciences is a small cap stock with a market cap of about 1.5 billion dollars.

How does Korsana Biosciences make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves KRSA stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow KRSA stock every day?

Add KRSA to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow KRSA daily

A free brief on Korsana Biosciences and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare KRSA: KRSA vs NVS, KRSA vs AZN, KRSA vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed